Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

291
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
291
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

31
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
31
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

865
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
865

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Management and perceptions of anemia and iron deficiency prior to cardiac surgery.

Archivos peruanos de cardiologia y cirugia cardiovascular·2026
Same author

Tropical Seed Trait Database: advancing seed functional ecology in the world's most biodiverse region.

The New phytologist·2026
Same author

Oral step-down vs full-course intravenous antibiotic therapy for infective endocarditis: Protocol for a systematic review and meta-analysis.

PloS one·2026
Same author

Comorbidity Clusters in Acute Heart Failure: Insights From the AMERICCAASS Registry.

Journal of the American Heart Association·2026
Same author

Young and elderly patients with acute myocardial infarction: a comparative study of percutaneous coronary intervention.

Acta cardiologica·2026
Same author

Survival in Adult Patients Undergoing Heart Transplantation 1995-2024: A Report of the RETRAC Registry.

Global heart·2026

相关实验视频

Updated: Sep 9, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

从指导方针到实践:在心血管风险非常高的患者中达到LDL-C - 分析EDHIPO MARCA注册表

Brayan Daniel Cordoba-Melo1,2, Sebastián Seni-Molina1, Juan Pablo Arango-Ibanez1,2

  • 1Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia.

Lipids in health and disease
|September 2, 2025
PubMed
概括
此摘要是机器生成的。

在高危患者中,低密度脂蛋白胆固醇 (LDL- C) 目标的实现仍然不理想,尽管接受了降脂疗法. 在冠状动脉疾病患者中,频繁的随访和组合治疗是改善脂质控制的关键.

关键词:
欧洲经济委员会/欧洲经济论坛指南目标LDL-C降脂疗法非常高的心血管风险

更多相关视频

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K

相关实验视频

Last Updated: Sep 9, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K

科学领域:

  • 心脏病学
  • 公共卫生

背景情况:

  • 心血管疾病是全球主要的死亡原因,而脂质障碍症对其进展有重大影响.
  • 尽管降脂疗法 (LLT) 取得了进展,但达到目标低密度脂蛋白胆固醇 (LDL- C) 水平仍然是许多患者面临的挑战.

研究的目的:

  • 评估哥伦比亚患者因冠状动脉疾病 (CAD) 导致心血管风险非常高的LDL- C目标的实现.
  • 评估目标的实现与ESC/EAS指南的更新保持一致.

主要方法:

  • 一项回顾性多中心研究 (EDHIPO MARCA) 涉及哥伦比亚11个机构的1788名CAD患者.
  • 根据ESC/EAS指南的更新,对三个时期 (2011-2012,2016-2017,2021-2022) 的LDL-C目标的实现进行了分析.
  • 数据包括冠状动脉图报告和医疗记录,LDL- C目标为< 70 mg/ dL和< 55 mg/ dL.

主要成果:

  • 在随访期间,总体LDL- C目标达到36. 6%.
  • 根据指南期间,目标实现率有所不同:12.1% (2011),42.3% (2016) 和36.2% (2019).
  • 随访频率增加与更高的目标实现相关 (32. 9% 随访1次与 44. 0% 随访4次).

结论:

  • 尽管在非常高的CVR患者中广泛使用LLT,但LDL- C目标的实现仍然不足.
  • 加强脂质控制可能需要更频繁的患者随访和除了他类药物之外更广泛的组合治疗.